论文部分内容阅读
目的:分析老年急性髓细胞白血病(AML)的临床及生物学特点,寻求有效治疗方法。方法:回顾性分析62例60岁以上AML患者的临床资料,包括临床特征、染色体、免疫分型及化疗效果。结果:完全缓解(CR)率27.7%,总有效率44.7%。诱导期死亡率32.7%。伴MDS病史者占27.4%,其CR率低于无MDS病史者(6.7%vs37.5%,P<0.05)。伴淋系抗原表达者占28.2%,其CR率低于仅有髓系抗原表达者(0vs37.5%,P<0.05)。CD34+者占71.8%,其CR率低于CD34-者(16.0%vs62.5%,P<0.05)。结论:老年AML总体缓解率低,死亡率高,在临床上有其特殊性,治疗上更强调个体化。
Objective: To analyze the clinical and biological characteristics of elderly acute myeloid leukemia (AML) and seek effective treatment. Methods: A retrospective analysis of 62 cases of AML patients over the age of 60 clinical data, including clinical features, chromosomes, immunophenotyping and chemotherapy. Results: The complete remission (CR) rate was 27.7% and the total effective rate was 44.7%. Induced death rate 32.7%. Patients with a history of MDS accounted for 27.4%, the CR rate was lower than those without a history of MDS (6.7% vs37.5%, P <0.05). With lymph node antigen expression accounted for 28.2%, the CR rate was lower than those with only myeloid antigen expression (0 vs37.5%, P <0.05). CD34 + accounted for 71.8%, the CR rate was lower than that of CD34- (16.0% vs62.5%, P <0.05). Conclusion: The overall remission rate of elderly AML with high mortality rate is clinically unique and more emphasis on individualized treatment.